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Introduction
The transferrin receptor, CD71 (TfR), is one of the most widely 
targeted receptors for development of targeted cancer diag-
nostics and therapeutics.1 This type II transmembrane glyco-
protein is responsible for cellular iron transport and is found at 
low levels on the surface of many normal cell types. However, 
the receptor is highly expressed on cells with increased prolif-
eration rates. In particular, increased expression is observed 
across a wide range of cancer cells where increased expres-
sion is associated with poor prognosis.2 Perhaps most inter-
estingly, the receptor is also expressed at high levels on the 
blood-brain barrier where it has been shown to be a route for 
ferrying cargoes across the blood-brain barrier.3
The natural ligand of this receptor, transferrin, has been 
used extensively for the generation of numerous targeted 
drug delivery strategies including the development of targeted 
toxins, some of which have gotten as far as clinical trials.4–7 
Aside  from  anti-integrin  binding  RGD  peptides,  transfer-
rin is perhaps the most commonly used targeting ligand for 
functionalizing  nanoparticles  for  nanoparticle-based  diag-
nostics and therapeutics.8,9 Nanoparticles in and of them-
selves have a tendency to accumulate in the fenestrations 
of tumors through a phenomenon known as the enhanced 
permeability and retention effect;10 however, greater gains, 
in  particular  extravasation  and  tissue  penetration,  can  be 
achieved  by  including  targeting  ligands  on  the  surface  of 
nanoparticles. Specifically, transferrin has previously been 
shown to enhance the effect of nanoparticle-based siRNA 
delivery in vivo.11
In  addition  to  the  natural  ligand,  transferrin,  a  variety  of 
antibodies1 and even peptides12 have been identified which 
target the transferrin receptor. More recently, Chen et al. 
reported the development of both RNA and DNA aptam-
ers which target the murine transferrin receptor and dem-
onstrated  that  a  DNA  aptamer-α-l-iduronidase  conjugate 
taken  up  by  α-l-iduronidase-deficient  mouse  fibroblasts 
cells  was  transported  to  lysosomes  where  it  alleviated 
glycosaminoglycan  accumulation.13  The  selected  aptam-
ers were specific for the mouse receptor but were, unfor-
tunately, composed of natural nucleotides rendering them 
highly susceptible to degradation by serum nucleases and 
thus limiting their utility.
We  report  here  the  development  of  nuclease-stabilized 
aptamers which target the human transferrin receptor and are 
readily internalized by human cells. Aptamers were selected 
using a two-stage selection scheme which combines strin-
gent selection against the recombinant protein followed by 
a “functional” selection on cells grown in media.14 Using this 
approach, we have identified a family of aptamers which are 
readily and robustly internalized by a variety of human cancer 
lines known to express this receptor. A sequence analysis 
of functional clones revealed a conserved core motif from 
which we developed a minimized aptamer. To demonstrate 
their potential utility, minimized aptamers were used to func-
tionalize siRNA-containing stable nucleic acid lipid particles 
(SNALPs).  Anti-TfR  targeted  SNALPs  showed  enhanced 
SNALP uptake and target gene knockdown in cells grown 
in culture when compared to nonmodified SNALPs or those 
bearing a nontargeting aptamer control.
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Results
Selection of anti-TfR aptamers
In order to identify nuclease-stabilized aptamers that target 
the human transferrin receptor and are readily endocytosed 
by cells, we used a hybrid in vitro selection protocol which 
combined stringent rounds of selection against recombinant 
protein with a function-based selection against cells. Selec-
tions were conducted using a 2′-fluoro-modified (2′F) RNA 
pool that contained a 50-nucleotide random sequence core 
flanked by primer binding sites. The 2′F modification can be 
readily incorporated during transcription by substituting 2′F 
CTP and 2′F UTP instead of the natural CTP and UTP and 
using the mutant T7 RNA polymerase protein Y639F.15,16 The 
resultant modified RNA is highly resistant to nuclease degra-
dation and thus suitable for in vivo use.17
An initial four rounds of selection were conducted using a 
His-tagged recombinant protein produced from Sf9 cells. For 
the initial round, we utilized ~three copies of a library com-
posed of ~1014 unique RNA sequences with ~2 µg recombi-
nant hTfR immobilized on 20 µl Ni-NTA agarose. Following 
stringent washing, bound RNA was recovered by elution with 
imidazole  and  subsequently  amplified.  Following  the  first 
round, we employed a negative selection step in which the 
library was preincubated with Ni-NTA agarose prior to the 
positive selection step. For rounds 2, 3, and 4, the stringency 
of the selection was increased by dropping the concentration 
of the target protein 100-fold. However, when we labeled the 
Round 4 population using a fluorescently labeled oligonucle-
otide complementary to the 3′ constant end of the library and 
analyzed the population’s ability to stain Jurkat cells by flow 
cytometry, little or no improvement in binding was observed 
over the starting Round 0 library (Figure 1a).
In  order  to  ensure  the  identification  of  aptamers  which 
could bind hTfR in the context of the cell surface and be read-
ily endocytosed while potentially minimizing nonspecific bind-
ing to the cell surface, following Round 4, we performed an 
“internalization selection” on live HeLa cells, a human cervical 
cancer cell line known to express TfR.14 In short, HeLa cells 
were incubated with the Round 4 aptamer library in media 
for 1 hour after which the cells were extensively washed and 
trypsinized. Following trypsinization, the recovered cells were 
treated with ribonuclease to remove any cell surface-bound 
RNA. Following an additional stringent wash, we used Trizol 
to extract total RNA from the cells, recovering any aptamers 
that were internalized by the cells and thus protected from 
nuclease treatment. The recovered RNA was subsequently 
Rounds
Clones
Cells
cells
Oligo only
R0
c7
c9
c11
R4
R5
c4
c2
0
100 101 102
Log AF488
103
Round 0
Clone
c2 (+) UCAAACAUCUCACAGAUCAAUCCAAGGGACCUCGUUAAAGGACGACUCCC
UAGGUUAGCGGCAGAUCACUACAAAGCCCCUAGAGCACAUGCUCCACCGCU
CAUUACGGCUACCCCGUGUAACGUCAGCCAAAGUAGACCAAAAGUCAG
ACGCAUGGCAGGAAGCAUGUUAUCCCCUAAGAAUCCGCAAUCGCUCGUAA
CAGAUGACAAAGCGCAUCAGAAGAAUAAAGUGAGAUAAAGUGUGAGAGGG
UUUGUGACCUGGUCAGGGAGUUGAAGGGUCGCUCUUUUGAAAAGCCUUGG
CCGCGAAACUUAAAAAAAACGACAAACGCGUGAGCCGGGCAAGGUAGUAUU
AGUAGCUUGAAAUCAGAAAACCGACGAAACAAAAAAUAUGAUUUAGCAAGGAUGACCACGUAAUUG
AGGGUGAAAUUGCGAGCGUUGCCCAACUUUAUAAGUUGGUGAAUAGCCA
ACAAGUAUCGGUUUUACAAUACAGACGUACAGUGCGAUAGCCAAGCGGAA
(+)
(+)
(−)
(−)
(−)
(−)
(−)
(−)
(−)
c4, c8
c11
c3
c1, c13
c5, c12
c7
c9
c10
c14
Activity sequence
Bright field AF546
clone c2
Transferrin
104
100 101 102
Log AF488
103 104
0
ab
d c
Figure 1  Selection of aptamer which bind the human transferrin receptor. (a) Progress of the selection. The aptamer library from 
indicated rounds was hybridized to an AF488-labeled reverse primer and assayed by flow cytometry for binding to Jurkat cells. “Oligo only” 
indicates cells treated with only the AF488-labeled reverse primer. (b) Sequence of clones isolated from Round 5 of the selection. Clones 
capable of binding Jurkats cells are indicated with a (+) whereas those which showed no staining are indicated with a (−). Sequences 
are shown without the 5′ and 3′ constant regions. (c) Analysis of selected clones by flow cytometry on Jurkat cells. Aptamer labeling was 
performed as in a. The identity of the clones is as indicated. (d) Bright field and fluorescent microscopy images of HeLa cells following 
incubation with RNA from Round 0 or the full-length clone 2 (100 nmol/l). RNAs were labeled by hybridization to AF546-labeled reverse 
primer. For comparison, cells were also imaged following treatment with biotinylated transferrin complexed to AF546-labeled streptavidin 
(100 nmol/l). Bars = 10 µm.
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amplified, and the Round 5 population was assayed by flow 
cytometry on Jurkat cells. As shown in Figure 1a, the Round 
5 population shows almost a tenfold improvement in binding 
when compared to Round 4 or Round 0.
We screened 13 clones (Figure 1b) from the round 5 pop-
ulation by flow cytometry on Jurkat cells and identified three 
variants which bound robustly to Jurkat cells (Figure 1c). 
Of note, while some sequences appeared multiple times in 
the population, only one of these (c4) turned out to be func-
tional based on our cytometric analysis. Importantly, when 
we  incubated  a  fluorescently  labeled  aptamer  (clone  c2) 
with HeLa cells grown in culture for 1 hour, the fluorescence 
could be clearly seen as punctate foci in the cell cytoplasm, 
consistent with the biology of trafficking of the transferrin 
receptor.
Characterization and minimization of anti-TfR aptamers
A  closer  inspection  of  the  sequences  of  individual  func-
tional  clones  identified  from  the  selection  revealed  short 
regions of sequence similarity (Figure 2a; red and blue). 
Strikingly, the three aptamers could be folded into a set of 
similar structures in which the conserved regions occupied 
nearly identical positions along the stem loop comprising 
a large asymmetric bulge of 12 nucleotides containing a 
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Figure 2  Comparison of anti-TfR binding clones c2, c4, and c11. (a) Sequences of clones c2, c4, and c11 with constant regions 
  (underlined). The additional 3′ constant region used for hybridization of a fluorescent probe for flow cytometry is not shown. Invariant resi-
dues shared between the clones are colored red. (b) Functional clones share a common fold. mfold predicted structure of c2, c4, and c11. 
Conserved residues highlighted in red (a) have been circled. The 5′ and 3′ ends of the sequences have been removed for clarity. (c) Mini-
mization of c2. Truncations were made by runoff transcription from the corresponding dsDNA templates. All sequences share an additional 
3′ constant region used for hybridization to a fluorescent probe for flow cytometry (data not shown). The conserved regions are highlighted 
in red. Residues added to start transcription, force pairing or introduce a tetraloop are indicated in green. The stem loop taken from c11 is 
indicated in blue. (d) mfold predicted structure of minimized anti-TfR aptamer c2.min. TfR, transferrin receptor.Molecular Therapy–Nucleic Acids
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conserved nonamer (GAUCAYUMC; where Y = U or C and 
M = A or C) and trimer (AMA) as well as a second smaller, 
cytosine-rich bulge situated 5–6 base pairs away (Figure 
2b). Using these structures as a guide, we generated and 
tested truncated versions of clone c2 to investigate the role 
of the conserved regions (Figure 2c). As expected, dele-
tion of the conserved 5′-nonamer (min.3) or modifications 
which converted the cytosine-rich bulge to a loop (min.4) or 
removed it entirely (min.5) resulted in a total loss of activity 
as determined by flow cytometry (Supplementary Figure 
S1). Of note, when we replaced the stem loop containing 
the cytosine-rich bulge from c11 on the large asymmetric 
bulge from c2, the clone retained full activity further sup-
porting the requirement of both of these regions (min.9). 
More importantly, our analysis allowed us to identify a mini-
mal aptamer comprised of 42 nucleotides, c2.min, in which 
we shortened the terminal stem formed between the 3′ and 
5′ ends and replaced the terminal loop with a stable GNRA 
tetraloop (Figure 2d). The chemically synthesized aptamer 
bound recombinant protein with a Kd of 102 nmol/l, ~five-
fold worse than the full length clone c2 (Kd = 17 nmol/l; 
Figure 3a).
We synthesized c2.min bearing a 3′inverted dT residue 
for added stability and a 5′ AlexaFluor 488 fluorescent tag to 
assess the molecule’s ability to bind cells. When incubated 
with Jurkat cells in media for 1 hour, dramatic staining was 
observed by flow cytometry at concentrations as low as 10 
nmol/l (Figure 3b). A plot of aptamer concentration versus 
mean fluorescence signal observed by cytometry yielded a 
Kdapparent on cells of 104 nmol/l, a value similar to the bind-
ing constant observed with the recombinant protein in solu-
tion (Figure 3c). Importantly, when we performed similar 
control experiments using a scrambled aptamer sequence, 
little or no background staining was observed (Figure 3c; 
cntrl.36).
Because the transferrin receptor is known to be overex-
pressed on numerous cancer cell lines, we assessed the 
ability of c2.min to bind different cells line. c2.min bound 
to every cancer cell line we tested including HeLa, 22Rv1, 
LnCAP,  PC3,  Ramos,  A431,  A549,  and  HT29  cells,  as 
shown  in  Figure  3d  (red).  Experiments  conducted  with 
murine  cell  lines  including  mouse  fibroblast  3T3  cells, 
mouse myoblast C2C12 cells, and T lymphocyte EL4 cells 
failed to show any staining, demonstrating that the aptamer 
is specific for the human receptor (data not shown). Impor-
tantly, no significant binding was observed when the same 
cell lines were tested using our control aptamer, cntrl.36 
(Figure 3d; blue).
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Figure 3  Binding analysis of anti-TfR clone c2. (a) Binding constant for the full-length aptamer c2 (red) or the minimized variant c2.min 
(blue) were determined by dual filter binding assay using 32P-labled RNA. The binding constants are as indicated. (b) Representative data 
for the determination of the apparent binding constant for the AF488-c2.min on Jurkat cells using flow cytometry. (c) Plot of the mean fluo-
rescence from data collected in b versus the aptamer concentration used to determine the apparent binding constant for c2.min on Jurkat 
cells. The binding constant is as indicated. (d) c2.min binds multiple different cancer cell lines. Flow cytometry experiments were performed 
at a final concentration of 100 nmol/l aptamer using either an AF488-c2.min (red) or a nonbinding control aptamer, AF488-cntrl.36 (blue). 
Unstained cells are shown in grey. The cell lines used for each experiment are as indicated. Each panel represents two or more experi-
ments. Kd, binding constant; TfR, transferrin receptor.www.moleculartherapy.org/mtna
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Efficient staining requires endocytosis
Endocytosis of the transferrin receptor is an energy-dependent 
process reliant on ATP.18 We therefore assessed the ability of 
c2.min to bind arrested cells. Of note, arrested cells (Figure 
4a; blue trace) showed no staining, suggesting that the off-
rate for aptamer binding is quite rapid, and it does not remain 
bound during the subsequent washing steps prior to cytomet-
ric analysis. No improvement in the staining of the arrested 
cells was observed when similar experiments were performed 
with the full-length aptamer clone c2 (data not shown), which 
displayed a lower apparent binding constant against recom-
binant protein. This result suggests that our selection method 
may  have  yielded  “functional”  aptamers  more  specifically 
tuned for internalization instead of aptamers that simply have 
a slow off-rate needed for high-affinity binding.
C2 competes with transferrin for binding the receptor
The  natural  ligand  for  the  transferrin  receptor,  transferrin 
(hTf), is present in blood at relatively high concentrations, 
~25 µmol/l with ~10–50% of this in the high-affinity mono-
ferric or diferric state.19,20 Therefore, we assessed whether 
or not our selected aptamer would compete with this natural 
ligand for receptor binding and uptake. Using flow cytometry, 
we assessed the uptake of AF488-labeled c2.min on Jurkat 
cells in the presence of increasing concentrations of diferric 
hTf. As shown in Figure 4b, as the concentration of diferric 
hTf was increased to 25 µmol/l, c2.min showed a decrease in 
binding with a plot of fraction aptamer bound versus the con-
centration of free transferrin yielding an IC50 of ~280 nmol/l 
(Figure 4c). A similar assay performed using fluorescently 
labeled iron-loaded transferrin instead of the aptamer yielded 
a  slightly  lower  IC50  (~150  nmol/l)  demonstrating  that  the 
aptamer binds to the receptor slightly better than the natural 
ligand.
We have also investigated the uptake kinetics of hTf and 
of the c2.min aptamer. Cells were coincubated with AF488-
labeled hTf and atto647N-labeled c2.min. Following a 30-min-
ute incubation, cells displayed the characteristic endosomal 
punctuated pattern obtained with labeled transferrin. More-
over,  c2.min  exhibits  a  vast  colocalization  with  transferrin 
(Figure 5a). When uptake was monitored over the course of 
a 60-minute period, the rates of uptake of the fluorescent car-
goes showed no differences (Figure 5b). Similar experiments 
in which cells were first loaded with either Tf-AF488 or c2.min-
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647N, washed and then placed in fresh media for different 
time  points  revealed  that  labeled  c2.min  washed  off  more 
slowly than labeled hTf (Figure 5c). This finding is consistent 
with the relative binding constants for iron free apo-transferrin 
(Kd = ~4 µmol/l)21 and the aptamer (Kd = ~100 nmol/l).
Enhanced delivery of siRNA using anti-TfR aptamers
In  order  to  assess  the  potential  to  deliver  molecular  car-
goes using anti-transferrin receptor aptamers, we generated 
siRNA-encapsulated  liposomes  containing  a  Cy5-labeled 
anti-enhanced green fluorescent protein (EGFP) siRNA and 
investigated gene knockdown in HeLa cells engineered to 
constitutively express EGFP (HeLa-EGFP).
Using a scalable, extrusion-free approach to making nucleic 
acid–loaded liposomes,22 we generated aptamer functional-
ized stable nucleic acid lipid particles (SNALPs) utilizing a 
lipid formulation previously shown to be effective at delivering 
siRNA both in mice and in nonhuman primates,23 but replacing 
the surface PEG-2000 molecules with a thiol-reactive PEG-
2000-malemide. Following siRNA encapsulation and dialysis, 
the thiol-reactive liposomes were incubated with either a thi-
ol-modified c2.min, a nonfunctional control aptamer (cntrl.36) 
or no aptamer at all (β-mercaptoethanol (BME)). Aptamer 
conjugations typically proceeded to ~90% within 4 hours as 
determined by gel electrophoresis (Supplementary Figures 
S2, S3, and S4). The liposomes were further characterized 
by  dynamic  light  scattering  and,  consistent  with  previous 
reports, found to be ~180 nm in diameter with a polydisper-
sity of ~20%.8,22,24 Aptamer conjugation resulted in a slight 
increase in liposome size (Table 1). Based on their size, the 
total mass of lipid used, and the concentration of aptamer 
used in the conjugation, we estimate that each liposome dis-
played ~60 aptamers per particle.
Liposome uptake (Cy5) and gene knockdown (EGFP) were 
assessed by flow cytometry using HeLa-EGFP cells 48 hours 
after treatment with aptamer-targeted or control SNALPs con-
taining a Cy5-labeled anti-EGFP siRNA. As shown in Figure 
6a, the c2.min-targeted SNALPs showed increased levels of 
uptake by cells when compared to both nontargeted SNALPs 
(BME) and those bearing the nonfunctional aptamer control 
(cntrl.36). More importantly, the enhanced uptake by the c2.min-
conjugated SNALPs also translated to an increased level of 
gene knockdown, as assessed by monitoring the decrease in 
the expression levels of the target protein EGFP (Figure 6b).
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Figure 5  Labeled c2.min and Tf were followed by fluorescent microscopy. (a) Confocal images of HeLa cells treated for 30 minutes 
with Tf-AF488 (50 µg/ml) and c2.min-647N (250 nmol/l) show subcellular colocalization. (b) Time courses of the uptake of Tf-AF488 or 
c2.min-647N were monitored over 60 minutes. HeLa cells were loaded for 5 minutes with labeled c2.min or Tf, washed and transferred to 
fresh media for different time points. (c) The loss of fluorescence was followed for 60 minutes. Data represent the average of three inde-
pendent experiments with 15–20 images per time point each. Error bars represent the SEM from three independent experiments. Bars = 
5 µm. SEM, standard error of the mean; Tf, transferrin.
Table 1  Characterization of liposome size by dynamic light scattering
Surface modification Diameter (nm) Polydispersity (%)
None 167 17
cntrl. 36 177 18
c2 190 20
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To confirm that uptake by c2.min-targeted SNALPs was 
mediated by binding and endocytosis via the transferrin recep-
tor,  we  performed  similar  experiments  using  HeLa-EGFP 
cells  and  SNALPs  loaded  with  a  Cy5-labeled  anti-EGFP 
siRNA but in the presence of free transferrin. Consistent with 
our  competition  studies  performed  with  the  free  aptamer 
(Figure 4b,c), c2.min-targeted SNALPs displayed reduced 
uptake when 25 µmol/l diferric transferrin was added to the 
cell culture media (Figure 6c). When the same cells were 
analyzed  for  EGFP  knockdown,  c2.min-targeted  SNALPs 
showed a significant decrease in the level of knockdown of 
EGFP (Figure 6d). The added transferrin had no effect on 
uptake or gene knockdown when treated with nontargeted 
(BME) or nonfunctional aptamer controls (Supplementary 
Figure S5). Gene knockdown and the mechanism of uptake 
were further confirmed by using real-time PCR to assess the 
level of EGFP mRNA degradation (Figure 6e).
To  ensure  specificity,  we  performed  similar  experiments 
using an alternate siRNA which targets the housekeeping 
gene lamin A/C. HeLa-EGFP cells treated with SNALPs con-
taining a Cy5-labeled anti-Lamin A/C siRNA showed similar 
levels of siRNA uptake but failed to show a decrease in EGFP 
signal (data not shown). In contrast, real-time PCR analysis 
of the treated cells revealed enhanced knockdown of lamin 
A/C  mRNA  when  treated  with  c2.min-targeted  SNALPs 
as  compared  with  nontargeted  SNALPs  or  those  bearing 
the nonfunctional aptamer control (Figure 6f). Importantly, 
when these experiments were performed in the presence of 
25 µmol/l diferric transferrin, only the samples treated with 
c2.min-targeted  SNALPs  were  affected,  returning  to  near 
background levels of mRNA knockdown.
Nanoparticles and liposomes often benefit from the fact 
that targeting ligands are displayed in a polyvalent manner 
which can lead to significant enhancements in binding affin-
ity through avidity effects.24,25 Indeed, at 200 nmol/l siRNA, 
the  concentration  used  in  our  delivery  experiments,  the 
concentration  of  liposomes  is  actually  ~300  pmol/l,  which 
is  far  below  the  observed  binding  constant  measured  for 
our aptamer (100 nmol/l). To explore this effect further, we 
performed uptake (Figure 6g) and knockdown experiments 
(Figure 6h) over a range of concentrations from 1 nmol/l to 
1 µmol/l siRNA (1.6 pmol/l to 1.6 nmol/l liposome). Liposome 
binding/uptake displayed an apparent Kd of 310 ± 130 pmol/l 
(Figure 6i), ~300-fold less than the aptamer alone. Gene 
knockdown displayed an EC50 of 74 ± 64 pmol/l (Figure 6i) 
demonstrating that the siRNA pathway saturates long before 
the cell uptake pathway does. Consistent with our previous 
results, little background uptake and almost no change in 
EGFP expression is observed when similar experiments are 
performed with nontargeted SNALP controls (Supplemen-
tary Figure S6).
Finally, the delivery of siRNA, especially via endosomal 
routes has the potential to lead to nonspecific immune activa-
tion.25 Therefore, we assessed the cellular immune response 
to cells treated with aptamer targeted SNALPs by monitoring 
the expression of OAS1, CDKL2, and interferon B by real-
time PCR. No increase in mRNA levels of these genes was 
observed indicating that aptamer-mediated SNALP delivery 
did not induce any adverse cellular effects (Supplementary 
Figures S7 and S8).
Discussion
Aptamers  that  target  cell  surface  receptors  have  great 
potential for development of both targeted diagnostics and 
therapeutics and have been a focus of many recent selec-
tion experiments (reviewed in refs (26,27)). One very prom-
ising target for targeted delivery is the transferrin receptor, a 
transmembrane protein that is highly overexpressed across 
a number of different cancer lines. Indeed, CALAA-0, a tar-
geted siRNA nanoparticle formulation which utilizes the natu-
ral ligand for this receptor, transferrin, has previously been 
shown to function in humans28,29 and is currently undergoing 
clinical trials.30 The transferrin receptor has also been shown 
to be expressed on the endothelium of the blood-brain bar-
rier, where targeting has been demonstrated as a way to 
enhance delivery to the brain.3,31
While both DNA and RNA aptamers to the murine transfer-
rin receptor have previously been reported, neither of these 
can be easily adapted for therapeutic or diagnostic purposes 
in humans, as they were selected against the mouse variant 
and do not cross react.13 Additionally, because these aptam-
ers  are  nonmodified  RNA  and  DNA,  they  are  not  serum 
stable and will require additional modifications and optimi-
zations before use in vivo. In experiments conducted in our 
laboratory, a FITC-labeled version of the anti-murine trans-
ferrin receptor DNA aptamer did not stain murine fibroblasts 
(3T3) or T cells (EL4) in media (data not shown). However, 
the apparent lack of observed binding might be the result 
of differences in valency and our cell staining approach, as 
Chen et al. reported staining using biotinylated aptamers and 
fluorescently labeled streptavidin.
We have generated nuclease-stabilized aptamers which 
bind the human transferrin receptor and are readily internal-
ized by cells, thereby providing a means to specifically deliver 
cargoes to human cells which express this receptor. To do 
this, we utilized a two-stage selection strategy in which we 
first enriched a nuclease-stabilized RNA library for molecules 
which could bind to recombinant protein. We then enriched 
for  molecules  which  had  the  desired  function—namely,  to 
bind the receptor on the surface of cells grown in tissue cul-
ture and to be internalized. Analysis of functional clones from 
the 5th round of the selection allowed for the identification 
of a core anti-TfR binding motif and a minimized aptamer, 
c2.min, that is specific for the human receptor and is robustly 
endocytosed by multiple cancer cell lines grown in culture. 
Of note, inhibition of endocytosis resulted in almost a com-
plete loss of cell staining as determined by flow cytometry 
(Figure 4b) suggesting that the off-rate for bound aptamers 
is relatively fast and that surface-bound molecules are lost 
during sample workup. This unexpected result may, in fact, 
be a direct consequence of the selection method which we 
employed. That is, by performing a functional selection for 
uptake, rather than just binding, we appear to have enriched 
for molecules which likely would not have been identified as 
they would have been lost from the cell surface during the 
subsequent wash steps of the selection process.
Because  the  natural  ligand  for  the  transferrin  receptor, 
transferrin, is present in blood at the relatively high concen-
tration  of  ~25  µmol/l,  we  assessed  whether  our  selected 
aptamers  would  compete  with  this  ligand  for  binding.  In Molecular Therapy–Nucleic Acids
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serum, transferrin exists in three major forms: the low affinity 
apo-form (Kd = ~4 µmol/l) and the high-affinity monoferric (Kd 
= ~200 nmol/l) and diferric forms (Kd = ~10 nmol/l).21 These 
high affinity forms of the protein are typically present at levels 
ranging from ~ 2 to10 µmol/l depending on the level of iron in 
the blood.19,20 In our titration experiments in which we utilized 
the high-affinity diferric transferrin as a competitor, significant 
aptamer binding and uptake were observed even at super-
physiological concentrations of free ligand. When compared 
to fluorescently labeled transferrin, our aptamer displayed a 
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more favorable IC50 (~twofold) than the natural ligand suggest-
ing that these molecules would serve as superior in vivo tar-
geting agents. However, because our aptamer does not bind 
the mouse receptor, care will have to be taken in evaluating 
this aptamer in vivo using human xenograft tumor models, as 
the aptamer will not likely bind to any tissues other than the 
tumor. Additionally, in vivo results may be further complicated 
by the fact that mouse transferrin binds the human transfer-
rin receptor with weaker affinity and, as expected, shows a 
sixfold higher IC50 when utilized in competition assays with 
c2.min (Supplementary Figure S9).
Because of its ability to be internalized into TfR-expressing 
cells, we explored the possibility of using this aptamer for 
delivery of potential therapeutics. Of particular interest is the 
delivery of siRNA, which can be designed to target almost 
any  gene.  One  attractive  strategy  for  aptamer-mediated 
siRNA delivery is the design of aptamer-siRNA chimeras.32–37 
Therefore, based on the designs reported by Dassie et al. 
(A10-SWAP),37 we generated aptamer-siRNA chimeras tar-
geting the gene PLK1 using our minimized aptamer c2.min 
as the targeting molecule. Unfortunately, while our aptamer-
siRNA  chimeras  were  readily  taken  up  by  HeLa,  LNCaP, 
and 22Rv1 cells at essentially the same levels as the free 
aptamer,  the  efficacy  of  the  delivered  siRNA  proved  very 
poor with no effect on cell viability observed (data not shown). 
Control experiments using the constructs reported by Dassie 
et al., which target the prostate-specific membrane antigen 
on LnCAP and 22Rv1 cells (two cell lines known to express 
prostate-specific membrane antigen) also failed to elicit any 
effect on cell viability even when delivered at 100 times the 
published minimal effective dose (400 nmol/l). The lack of 
efficacy of this approach prompted us to explore alternate 
methods for the delivery of siRNA.
Nanoparticle-based  delivery  systems  are  gaining  much 
interest both in the laboratory and in the clinic, and aptam-
ers have previously been shown capable of enhancing the 
delivery of nanoparticle and liposomal small molecule drug 
formulations.38–42  With  an  interest  in  targeting  siRNA,  we 
tested our aptamer for its ability to enhance delivery of nano-
particle-based siRNA formulations. In particular, we chose to 
investigate a lipid nanoparticle formulation called SNALPs 
(stable  nucleic  acid  lipid  particles),  which  have  previously 
been used to deliver siRNA to liver cells as well as solid 
tumors43 and are currently undergoing clinical trials.44,45 While 
these neutral liposomes have been shown to associate with 
Apo-E leading to efficient liver uptake, more recent work has 
demonstrated that the particles and their siRNA cargoes can 
be specifically targeted to other receptors by functionalizing 
the liposomal surface with ligands.46 To this end, we synthe-
sized maleimide functionalized SNALPs using an extrusion-
free approach.47 This yielded liposomes approximately ~200 
nm in diameter which we subsequently derivatized with a 
thiol-modified,  minimized  anti-TfR  aptamer,  c2.min.  While 
the utility of liposomes this size may be somewhat limited 
in vivo, they serve as a convenient platform to demonstrate 
the potential utility of our aptamers, at least in vitro. In this 
regard,  the  ease  with  which  aptamers  can  be  chemically 
synthesized and site specifically modified makes them ideal 
candidates for chemical conjugation and functionalization of 
nanoparticles.
Anti-TfR  targeted  SNALPs  displayed  both  enhanced 
uptake  and  enhanced  target  gene  knockdown  when  com-
pared to SNALPs bearing a maleimide group which had been 
quenched with BME or those bearing a nontargeting control 
aptamer (Figure 6a). SNALPs bearing the control aptamer 
performed worse than those quenched with BME suggesting 
that the negatively charged molecules on the surface of the 
liposome may inhibit interactions with serum ApoE and hinder 
uptake by this mechanism. To confirm the route of uptake of 
our anti-TfR targeted SNALPs, we performed experiments in 
the presence of 2 mg/ml human holotransferrin (diferric). As 
observed,  with the free aptamer, at this concentration of free 
ligand, liposome binding was significantly decreased as was 
the observed gene knockdown, confirming the link between 
receptor targeting and the observed enhanced function.
In summary, by combining a “traditional” selection approach 
using recombinant protein with a functional selection for inter-
nalization, we have identified aptamers that bind the human 
transferrin receptor and are readily internalized by cells. We 
envision that this hybrid selection approach may prove useful 
for other cell surface targets which are known to be inter-
nalized  or  where  the  desired  function  is  aptamer-induced 
internalization. Perhaps more importantly, using a minimized 
anti-TfR aptamer identified by this selection approach, we 
generated aptamer-targeted SNALPs and have shown that 
receptor  targeting  enhances  cell  uptake  and  more  impor-
tantly the efficiency of gene knockdown on cells grown in tis-
sue culture. Aptamer-targeted liposomes may therefore play 
an important role in the future development of nanoparticle-
based siRNA therapies.
Figure 6  Analysis of liposome /siRNA uptake and gene knockdown using aptamer-targeted SNLAPs. (a) Uptake of SNALPs loaded 
with Cy5-labeled anti-EGFP siRNA and (b) knockdown of EGFP in HeLa-EGFP cells as determined by flow cytometry. Cells only (cells), 
targeted (c2.min), or nontargeted SNALPs (BME and cntrl.36) are as indicated. Transfection of the same Cy5-labeled anti-EGFP siRNA 
using HiPerfect was included for comparison (Transfection). Cells were treated as indicated for 24 hours, after which the media was 
changed. Cells were analyzed 48 hours after initial exposure to SNALPs. (c) Uptake of Cy5-labeled siRNA and (d) knockdown of EGFP in 
HeLa-EGFP cells in the absence or presence of 25 µmol/l diferric human transferrin as determined by flow cytometry. Similar experiments 
using nontargeted SNALPs (BME and cntrl.36) can be found in Supplementary Figure S5. Data are representative of a minimum of three 
independent experiments. (e,f) qPCR analysis monitoring mRNA levels in HeLa-EGFP cells treated with SNALPs containing an anti-EGFP 
siRNA (e) or anti-Lamin A/C siRNA (f) in the absence or presence (+ Tf) of 25 µmol/l transferrin. Cells only (cells), targeted (c2.min), or non-
targeted liposomes (BME and cntrl.36) are as indicated. Cells were treated as indicated for 24 hours, after which the media was changed. 
Cells were analyzed 48 hours after initial exposure to SNALPs. All data represent the average of two or more independent trials using 
independent preparations of liposomes. (g,h) Concentration dependence of c2.min-targeted uptake and gene knockdown in HeLa-EGFP 
cells. Experiments were conducted as described in a. Concentrations are as indicated. Untreated cells (cells) are shown in grey. Similar 
experiments using nontargeted SNALPs (BME and cntrl.36) can be found in Supplementary Figure S6. (i) Plot of liposome concentration 
versus mean fluorescence of Cy5 uptake (black) and EGFP knockdown (red). SNALP, stable nucleic acid lipid particle; Tf, transferrin.Molecular Therapy–Nucleic Acids
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Materials and methods
Cell lines and tissue culture. All cells were obtained from the 
American Tissue Culture Collection (ATTC, Manassas, VA). 
HeLa,  A431,  and  HT29  cells  were  cultured  in  Dulbecco’s 
Modified Eagle Medium (DMEM) (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (FBS) (Invitro-
gen). Jurkat, Ramos, 22Rv1, and LnCap cells were cultured 
in RPMI-1640 (Invitrogen) supplemented with 10% FBS. PC3 
and A549 cells were cultured in F12K (Invitrogen) supple-
mented with 10% FBS. All cells were grown at 37 °C with 5% 
CO2 and 99% humidity. Sf9 insect cells were grown at 27 °C 
in Grace’s Insect Media (Invitrogen).
Protein production and purification. The plasmid pAcGP67A-
TfR (Addgene, Cambridge, MA) was used to express human 
transferrin  receptor  (hTfR)  in  insect  cells  (Sf9).  The  His-
tagged protein was purified on Ni-NTA agarose, dialyzed to 
remove imidazole and concentrated to ~1 mg/ml for storage.
Selection  of  nuclease-stabilized  anti-TfR  aptamers.  The 
sequence of the N50 library used for selection was 5′GGG-
AGGTGAATGGTTCTACGAT-N50-TTACATGCGAGATGACC
ACGTAATTGAATTAAATGCCCGCCATGACCAG-3′. The sin-
gle-stranded DNA library was synthesized such that N regions 
contained an equal probability of containing A, T, G, or C, as 
previously described.48 Following deprotection, the library was 
gel purified by denaturing (7 mol/l urea) gel electrophoresis on 
an 8% polyacrylamide gel. The   single-stranded DNA library 
was amplified by PCR to generate double-stranded DNA bear-
ing a T7 promoter. The double-stranded pool was transcribed 
in vitro using the Y639F mutant of T7 RNA polymerase15,16 
and 2′-fluoro (2′F) pyrimidines. The RNA was purified on a 
denaturing (7 mol/l urea) 8% polyacrylamide gel.
For the initial round of selection, we utilized ~3 copies of 
a library composed of ~1014 unique RNA sequences. Prior 
to each round, the library was thermally equilibrated in 30 
µl HBSS (Hank’s Buffered Saline Solution; Invitrogen) for 3 
minutes at 70 °C and allowed to cool on the benchtop for 
at least 15 minutes. The sample was subsequently supple-
mented with 0.1% bovine serum albumin, 1 µg/µl ssDNA and 
tRNA in a final volume of 50 µl of HBSS.
The thermally equilibrated aptamer library was incubated 
with 2 µg of recombinant hTfR immobilized on 20 µl of Ni-
NTA  agarose.  Following  a  30-minute  incubation  at  room 
temperature, the resin was washed five times with 500 µl of 
HBSS, and then protein-bound RNA was eluted by the addi-
tion of 400 µl HBSS containing 200 mmol/l imidazole. Eluted 
RNA was recovered by ethanol precipitation, reverse tran-
scribed, PCR amplified and retranscribed into RNA for the 
subsequent round. Following the first round, we employed a 
negative selection step in which the library was preincubated 
with 200 µl of Ni-NTA agarose prior to the positive selection 
step. For rounds 2, 3, and 4, we utilized 5 µg of RNA, and 
the stringency of the selection was increased by dropping the 
number of target protein by 100-fold. This was achieved by 
resuspending 2 µg of protein immobilized on 20 µl of Ni-NTA 
agarose in 200 µl of HBSS and using 2 µl of the well-mixed 
slurry. For these rounds, washing was facilitated by using a 
0.45-micron spin filter to capture the trace amount of Ni-NTA 
resin. All incubations and washes (6 × 400 µl) were performed 
at 37 °C.
For Round 5, we performed an “internalization selection” 
using HeLa cells. To ensure that selected aptamers could eas-
ily be assayed by flow cytometry, the pool was combined with 
a 1.5-fold molar excess of reverse primer bearing a 5′ fluores-
cent dye (AF488-CTGGTCATGGCGGGCATTTAATTC). Fol-
lowing thermal equilibration in 50 µl of HBSS, the library was 
added to one well of a 24-well plate containing ~105 adherent 
HeLa cells in 300 µl DMEM supplemented with 10% FBS and 
1 mg/ml tRNA and ssDNA (Sigma, St. Louis, MO) as blocking 
agents. Following a 1-hour incubation at 37 °C, the cells were 
washed three times with 1 ml HBSS containing 0.1% sodium 
azide, once with 1 ml cold 200 mmol/l glycine and 150 mmol/l 
NaCl at pH 4, and three more times with HBSS. Cells were 
then lifted with 500 µl trypsin-EDTA containing 0.1% sodium 
azide, removed from the plate, washed with 1 ml HBSS, and 
resuspended in 100 µl HBSS containing 5 µl Riboshredder 
RNAse cocktail (Epicentre, Madison, WI). Following a 5-min-
ute incubation at room temperature, the cells were washed 
an additional three times with 1 ml of HBSS, and the total 
cellular RNA was recovered using Trizol extraction according 
to manufacturer’s protocol (Invitrogen). The recovered RNA 
was reverse transcribed, amplified by PCR, and transcribed 
back into RNA.
Minimized aptamers were generated by runoff transcription 
using the Y639F RNA polymerase and 2′-fluoro (2′F) pyrimi-
dines. The RNA was purified on a denaturing (7 mol/l urea) 
8% polyacrylamide gel. The minimized 2′F RNA variants all 
bore the same 3′ constant region (GAATTAAATGCCCGCCA-
TGACCAG), which allow for hybridization of reverse primer 
bearing a 5′ fluorescent dye. Binding assays were conducted 
using flow cytometry as described above.
Chemical  synthesis  of  RNA  aptamers.  The  minimized 
aptamer was synthesized in our laboratory on an Expedite 
8909 DNA synthesizer (Applied Biosystems, Carlsbad, CA) 
using  2′-fluoro-deoxycytidine  and  2′-fluoro-deoxyuridine 
phosphoramidites  (Metkenin,  Kuusisto,  Finland).  Unless 
noted  otherwise,  all  reagents  were  purchased  from  Glen 
Research (Sterling, VA). The aptamer was synthesized bear-
ing a 5′ thiol modification using a thiol-modifier C6 S-S phos-
phoramidite and a 3′ inverted dT residue for added serum 
stability. The sequences of the minimized aptamer, c2.min, 
and  a  nonbinding  aptamer,  cntrl.36,  were:  5SGGGGGAU-
CAAUCCAAGGGACCCGGAAACGCUCCCUUACACCCCt 
and  5SGGCGUAGUGAUUAUGAAUCGUGUGCUAAUA-
CACGCCt,  respectively,  where  “t”  is  a  3′inverted  dT  and 
“5S” is the 5′ thiol. All aptamers were synthesized with the 
final dimethoxytrityl group on to facilitate purification. Follow-
ing deprotection, aptamers were purified by reversed-phase 
HLPC on a 10 × 50 mm Xbridge C18 column (Waters, Mil-
ford, MA) using a linear gradient of acetonitrile in 0.1 mol/l 
triethylammonium acetate at pH 7.0.
Thiolated  aptamers  were  used  to  generate  the  Alex-
aFluor488  (AF488)-  or  Atto-647-labeled  aptamers  used 
in cytometry or microscopy. Labeling was performed using 
AF488-C5-malemide  (Invitrogen)  or  Atto-647-malemide 
(ATTO-TEC  GmbH,  Siegen,  Germany)  as  follows:  10 
nmoles  thiolated  aptamer  was  reduced  using  10  mmol/l www.moleculartherapy.org/mtna
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tricarboxyethylphosphine in 100 µl of 0.1 mol/l TEAA. Sam-
ples were heated at 70 °C for 3 minutes followed by incuba-
tion at room temperature for 1 hour. The reduced aptamers 
were desalted using Biospin 6 columns (BioRad, Hercules, 
CA) into phosphate-buffered saline (PBS) supplemented with 
50 mmol/l phosphate pH 7.5. To this, 10 µl of dimethyl sulfox-
ide  was added containing the fluorescent maleimide. Follow-
ing an overnight reaction at 4 °C, the aptamer was recovered 
by ethanol precipitation, resuspended in PBS, and desalted 
an additional time using a Biospin 6 column. Dye to aptamer 
ratios were determined at 260 and 650 nm and were typically 
~1. The absence of free dye in the final product was con-
firmed by reversed-phase HLPC.
Aptamer  binding  by  flow  cytometry.  Aptamer  binding  and 
uptake was assessed by flow cytometry. Rounds from each 
selection  or  isolated  clones  were  first  hybridized  to  the 
AF488-labeled reverse primer complementary to the 3′ end 
of the library. Rounds or individual aptamers were incubated 
at 1 µmol/l with 1.5 µmol/l biotinylated oligonucleotide in Dul-
becco’s phosphate-buffered saline (DPBS) heated to 70 °C 
for 3 minutes and then allowed to cool on the bench top for 15 
minutes. Following hybridization, the aptamers were added 
to cells in the appropriate media supplemented with 1 µg/
ml tRNA and sheared salmon sperm DNA (ssDNA) at final 
concentration of 100 nmol/l.
For  assays  conducted  on  suspension  cells,  ~150,000 
cells were incubated in a final reaction volume of 50 µl. For 
adherent cells, ~100,000 cells were incubated per well in a 
24-well plate in 100 µl final volume. Unless otherwise noted, 
rounds/aptamers  were  incubated  with  cells  for  1  hour  at   
37 °C. Following incubation, adherent cells were trypsinized 
with 100 µl trypsin-EDTA for 5 minutes. The reaction was 
quenched by the addition of 1 ml fluorescence-activated cell 
sorting (FACS) buffer, and the cells were pelleted and washed 
an additional time with FACS buffer before being resuspended 
in 500 µl FACS buffer containing 2 µg/ml 7-aminoactinomycin 
D stain (7AAD) to exclude dead cells in the analysis. Flow 
cytometry was performed on a FACScan or FACScalibur flow 
cytometer (Beckton Dickinson, Franklin Lakes, NJ).
Fluorescence microscopy. For microscopic analysis of Round 
0 and full-length c2 on HeLa cells, RNA was labeled by hybrid-
ization  to  an  AF546-labeled  oligonucleotide  as  described 
above for the flow cytometry experiments. As a control, 1 
µmol/l biotinylated transferrin (Invitrogen) was preincubated 
with 1 µmol/l AF546-labeled streptavidin (Invitrogen). HeLa 
cells were grown as adherent monolayers in eight-chamber 
glass  slide  systems  (Labtek;  Nunc  Nalgene  International, 
Rochester, NY). Thirty minutes prior to aptamer treatment, 
cells were blocked with 0.1 µg/ml tRNA and ssDNA in DMEM 
supplemented with 10% FBS at 37 °C. Labeled Round 0, c2 
or transferrin was added to the media to a final concentration 
of 100 nmol/l, and the samples were incubated at 37 °C for 1 
hour, after which the media was changed, and the cells were 
imaged on an Olympus IX71 inverted microscope.
Colocalization  images  (Figure  5a)  of  hTf-AF488  and 
c2.min-647N were obtained using a true confocal scanner 
SP5  fluorescence  microscope  from  Leica  Microsystems 
GmbH, with a 1.4 N.A., ×100 objective (Leica Microsystems 
GmbH). HeLa cells were exposed simultaneously to Tf-AF488 
(50 µg/ml) and c2.min-647N (250 nmol/l) for 30 minutes in 
Ringer buffer containing 10 µg/ml each of yeast tRNA and 
ssDNA as blocking agents. Coverslips were then taken out, 
washed  thoroughly  with  Ringer  buffer,  and  placed  in  ice-
cold paraformaldehyde (4%) for 30 minutes. Samples were 
quenched for 10 minutes with PBS containing 100 mmol/l of 
glycine and NH4Cl. Finally, cells were mounted in Mowiöl.
Uptake and washout experiments of transferrin or aptamer 
were imaged with an Olympus IX71 microscope equipped 
with 1.45 NA/×100 objective. Images were captured with an 
Olympus F-View II CCD camera (all from Olympus, Hamburg, 
Germany). For uptake experiments, HeLa cells were washed 
in Ringer buffer (124 mmol/l NaCl, 5 mmol/l KCl, 2 mmol/l 
CaCl2, 1 mmol/l MgCl2, 30 mmol/l d-glucose, and 25 mmol/l 
HEPES, pH 7.4) and exposed to a mixture of Tf-AF488 (50 
µg/ml) and c2.min-647N (250 nmol/l) prepared in Ringer buf-
fer containing 10 µg/ml each of yeast tRNA and ssDNA as 
blocking agents. After the specified times, coverslips were 
washed thoroughly, fixed in ice-cold paraformaldehyde (4%) 
for 30 minutes and then quenched for 10 minutes with PBS 
containing  100  mmol/l  of  glycine  and  NH4Cl.  Finally,  cells 
were mounted in Mowiöl.
For monitoring the loss of fluorescence, HeLa cells were 
washed  in  Ringer  buffer  and  exposed  for  5  minutes  to  a 
mixture of Tf-AF488 (50 µg/ml) or c2.min-647N (250 nmol/l) 
prepared in Ringer buffer containing 10 µg/ml each of yeast 
tRNA and ssDNA as blocking agents. Cells were then briefly 
washed with a large volume (100 ml) of Ringer buffer and 
placed back into their complete medium inside the incuba-
tor (37 °C and 5% CO2). After the specified times, coverslips 
were taken out, washed with Ringer buffer, and placed in ice-
cold paraformaldehyde (4%) for 30 minutes. Samples were 
quenched for 10 minutes with PBS containing 100 mmol/l of 
glycine and NH4Cl. Finally, cells were mounted in Mowiöl.
Graphs represent the average data obtained from three 
independent experiments with 15–20 images per time point 
each. Error bars represent standard error of the mean (SEM) 
from three independent experiments.
Determination of binding constants. Binding constants were 
determined by nitrocellulose filter binding assays.49 Aptamers 
were radiolabeled using T4 PNK (Optikinase; USBiologicals, 
Swampscott,  MA)  and  γ-32P-ATP  (Perkin  Elmer, Waltham, 
MA) following standard protocols. The full-length c2 aptamer 
was generated by transcription as described above, and the 
terminal triphosphate was removed by treatment with alkaline 
phosphatase (FastAP; Fermentas, Glen Burnie, MD) prior to 
kinasing.
For each assay, the aptamer was thermally equilibrated in 
tissue culture grade DPBS containing Mg2+ and Ca2+ (Invitro-
gen) by heating at 70 °C for 3 minutes followed by incubation 
at room temperature for 15 minutes. Ten fmoles of radiola-
beled  aptamer  was  combined  with  varying  concentrations 
of protein in a total volume of 50 µl in DPBS. Binding was 
allowed to come to equilibrium for 30 minutes at room tem-
perature, and bound species were partitioned from unbound 
species by passing through nitrocellulose and nylon filters 
under  vacuum  followed  by  three  successive  washes  with 
500  µl  DPBS.  Filters  were  exposed  to  phosphor  screens 
overnight which were then imaged using a Storm Molecular Molecular Therapy–Nucleic Acids
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Imager Phosphorimager (GE Healthcare, Piscataway, NJ). 
The  fraction  of  bound  aptamer  was  determined  using  the 
ImageQuant software. Kinetic constants were determined by 
plotting the fraction of bound aptamer against concentration 
of hTfR, and data were fit to equation (1).
where f = fraction of bound aptamer, F = maximum fraction 
of bound aptamer, A = concentration of human transferrin 
receptor, and Kd = affinity dissociation constant.
For  determination  of  apparent  binding  constants  by  flow 
cytometry, 100,000 Jurkat cells were incubated with increas-
ing  concentrations  of  AF488-labled  c2.min  in  RPMI-1640 
supplemented with 10% FBS and 1 mg/ml tRNA and ssDNA 
in 50 µl. Following a 1-hour incubation at 37 °C, the cells were 
washed twice with 1 ml FACS buffer and then resuspended in 
500 µl FACS buffer containing 7AAD to exclude dead cells in 
the analysis. The apparent binding constant was determined 
from a fit of the mean fluorescence versus the aptamer con-
centration using the equation (1).
Transferrin  competition  binding  assays.  Assays  were  per-
formed  by  flow  cytometry  on  Jurkat  cells.  Aptamers  were 
thermally equilibrated in tissue culture grade DPBS contain-
ing Mg2+ and Ca2+ by heating at 70 °C for 3 minutes followed 
by incubation at room temperature for 15 minutes prior to 
addition to cells. For each reaction, 105 cells were preblocked 
by incubation in 50 µl RPMI containing 10% FBS and 1 mg/ml 
ssDNA and tRNA at 37 °C for 15 minutes prior the addition of 
100 nmol/l labeled aptamer (c2minAF488 or cntrl.36AF488) 
or 100 nmol/l labeled iron-loaded transferrin (Dy488-Tf; Jack-
son ImmunoResearch West Grove, PA) and unlabeled com-
petitor (25 µmol/l, 2.5 µmol/l, 250 nmol/l, 25 nmol/l, or 2.5 
nmol/l) in a final volume of 100 µl RPMI containing 10% FBS 
and 0.5 mg/ml ssDNA and tRNA. Cells were incubated at 
37 °C for 1 hour in 96 well tissue culture plates after which 
cells were washed three times with 1 ml FACS buffer before 
being resuspended in 500 µl FACS buffer containing 2 µg/ml 
7-aminoactinomycin D stain (7AAD) to exclude dead cells in 
the analysis. Data shown are the average of two independent 
trials. To ensure iron loading of the labeled transferrin, we 
performed similar experiments using Dy488-transferrin which 
had been pretreated by incubation in 400 µg/ml ferric ammo-
nium citrate 10 mmol/l NaHCO3/20 mmol/l HEPES pH 7.7 
for 10 minutes followed by desalting.50 Similar results were 
observed (data not shown).
Liposome  preparation.  SNALPs  were  prepared  using  the 
spontaneous vesicle formation by ethanol dilution method.22 
1,2-Distearoyl-sn-glycero-3-phosphocoline  (DSPC),  choles-
terol, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[maleimide(polyethylene  glycol)-2000]  (DSPE-PEG-Mal) 
were  purchased  from  Avanti  Polar  Lipids  (Alabaster,  AL). 
1,2-dilinoleyloxy-N,N-dimethyl-3-aminopropane  (DLinDMA) 
was synthesized following the method described by Heyes 
et al.24 siRNA was purchased from Integrated DNA Technolo-
gies (Coralville, IA).
A 90% vol/vol ethanol solution was prepared containing 10 
µmole of total lipid consisting of DSPC/DLinDMA/Cholesterol/
DSPE-PEG-Mal  (10:40:48:2  mol%).  A  second  solution  of 
equal volume was prepared containing siRNA at a 1:10 molar 
ratio of Cy5-labeled siRNA to unlabeled siRNA in 20 mmol/l 
citrate buffer pH 5.0. The amount of anti-GFP or antiLamin 
A/C siRNA added maintained a 2:1 (+/−) charge ratio based 
on the molar amounts of negatively charged siRNA and posi-
tively charged DLinDMA. Both solutions were heated to 37 
°C prior to vesicle formation. The siRNA solution was then 
added to the lipid solution with rapid mixing. The final mixture 
was diluted with an equal volume of 20 mmol/l citrate pH 6.0 
containing 300 mmol/l NaCl and mixed well by rapid pipetting. 
The resulting mixture was incubated at 37 °C for 30 minutes 
followed by dialysis with a 10 kDa membrane into PBS, pH 8.0 
with 1 mmol/l EDTA overnight at 4 °C. siRNA encapsulation 
efficiency typically exceeded 90% and was determined using 
Quant-iT RiboGreen (Invitrogen) as previously described24 or 
by gel electrophoresis as described below.
Thiol-modified aptamers were reduced prior to SNALP 
conjugation  by  adding  Tris-(2-carboxyethyl  phosphine) 
(TCEP) at a final concentration of 20 mmol/l, heating at 70 
°C for 3 minutes, and incubating at room temperature for 2 
hours. TCEP was removed by passing the sample through 
a Micro Bio-Spin 6 column (BioRad). After dialysis, thiol-
modified aptamers were added to the liposomes at a final 
concentration of 1.5 µmol/l and incubated for 4 hours at 4 
°C. Free maleimide groups were quenched after aptamer 
conjugation  with  1  mmol/l  BME  and  incubated  at  room 
temperature for 3 hours. SNALPs used for transfection pur-
poses were BME-quenched (nontargeted with no aptamer), 
cntrl.36-conjugated (nontargeted with a conjugated control 
aptamer), and c2-conjugated (targeted).
Liposome  characterization.  Particle  size  distribution  was 
assessed by dynamic light scattering (DynaPro Plate Reader, 
Wyatt Technology). SNALPs were diluted 1:40 in PBS and 
analyzed in a 384 well plate after removing bubbles by cen-
trifugation at 1,000g for 3 minutes.
Aptamer  conjugation  and  siRNA  encapsulation  were 
analyzed by running each sample on a denaturing (7 mol/l 
urea) 20% acrylamide gel. Samples were diluted 1:1 in 7 
mol/l urea loading buffer and subsequently loaded on the 
gel without heating. Under these conditions, the liposomes 
remained intact and trapped in the well while any unencap-
sulated  siRNA  or  unconjugated  aptamer  ran  into  the  gel. 
Gels were stained with SYBR Gold and imaged on a Storm 
840 phosphorimager (GE Health Sciences). The amount of 
free aptamer and siRNA was determined by comparison to 
aptamer or siRNA standard curve (Supplemental Figures 
S2, S3, and S4). Aptamer functionalized and nonfunctional-
ized liposomes were stable for at least 1 week when stored 
at 4 °C (Supplementary Figure S10).
The number of aptamers per liposome was estimated based 
on the observed conjugation efficiency and the concentration 
of liposomes. Liposome concentration was estimated based 
on the average diameter of these liposomes (~180 nm), the 
lipid surface area for packing of a phospholipid, 0.6 nm2, and 
by assuming that the liposomes are unilamellar and have 
spherical geometry.51
f
A
=
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Cell transfection. HeLa-EGFP cells (20,000 cells/well) were 
seeded  in  a  24-well  plate  in  DMEM/High  Glucose  culture 
medium  supplemented  with  5%  FBS  and  antibiotics  (D5 
media). Twenty-four hours later, D5 media was replaced with 
D5 supplemented with 10 mg/ml ssDNA in DPBS and 10 
mg/ml tRNA in DPBS, as blocking agents. BME-quenched, 
cntrl.36 nontargeted or c2 targeted SNALPs containing either 
GFP or LaminA/C siRNA were added to cells at a final siRNA 
concentration in each well of 200 nmol/l and cultured for 24 
hours at 37 °C. As a positive control, cells were transfected 
with either 7.5 ng GFP or 7.5 ng LaminA/C siRNA and 3 µl 
HiPerFect Transfection Reagent (QIAGEN, Valencia, CA) fol-
lowing the manufacturer’s protocol. As a negative control, 3 
µl HiPerFect in 100 µl Opti-MEM was added to cells growing 
in 500 µl D5. After a 24-hour incubation with liposomes or 
transfection reagent, all media was replaced with fresh D5 
media and cells were further incubated for 24 hours before 
assaying.
Flow cytometry and RNA isolation. Transfected cells were 
washed with PBS and trypsinized. Half of the cells in each 
sample were centrifuged at 300g for 3 minutes and resus-
pended in flow cytometry buffer consisting of HBSS with 1% 
bovine serum albumin and 0.1% sodium azide. Bisbenzimide 
was added to the buffer to assess cell viability. These samples 
were analyzed for knockdown of GFP expression and uptake 
of Cy5-siRNA on a Sony iCyt Eclipse Analyzer. The second 
half of each sample was passed through a QIAshredder cell 
homogenizer (QIAGEN). Total cell RNA for each sample was 
isolated from the cell lysate according to QIAGEN’s RNAeasy 
Plus Mini Kit protocol.
Real-time PCR. cDNA synthesis was performed by first heat-
ing the following components to 70 °C for 3 minutes: 100 ng 
of total RNA isolated as described above, 25 ng of random 
hexamer primers (Invitrogen), and 2 µl of 5× First Strand RT 
buffer (Invitrogen). Mixtures were cooled to 4 °C, and 2 µl of 
4 mmol/l dNTP mix, 1 µl of 0.1 mol/l DTT, and 1 µl of Molo-
ney murine leukemia virus reverse transcriptase (Invitrogen) 
were added to each mixture. Distilled water was added to 
each sample to make 10 µl final volume reactions. Samples 
were heated to 37 °C for 50 minutes followed by a 15-minute 
incubation at 75 °C.
Expression levels of GFP mRNA and LaminA/C mRNA 
were  analyzed  by  quantitative  real-time  PCR  on  an 
Applied Biosystems 7300 Real Time PCR machine using 
TaqMan Univeral Master Mix II (Invitrogen) and specific 
primer sets. GFP expression was measured using the fol-
lowing primers: GFP-For 5′GACAACCACTACCTGAGCAC, 
GFP-Rev  5′CAGGACCATGTGATCGCG,  and  GFP-probe 
5′FAM-CCTGAGCAAAGACCCCAACGAGAA-IBFQ. 
LaminA/C  expression  was  measured  using  the  follow-
ing  primers:  Lam-For  5′  ATGATCGCTTGGCGGTCTAC, 
Lam-Rev 5′, GCCCTGCGTTCTCCGTTT and Lam-probe 
5′  FAM-TCGACCGTGTGCGCTCGCTG-IBFQ.  RPLP0 
expression was used as a standard control with primers: 
RPLP0-For  5′GGCGACCTGGAAGTCCAACT,  RPLP0-
Rev  5′CCATCAGCACCACAGCCTTC  and  RPLP0-probe 
5′FAM-ATCTGCTGCATCTGCTTGGAGCCCA-IBFQ.52 
Reverse  transcription  reactions  were  diluted  1:40,  and 
10 µl of each sample was used in each 25 µl quantitative 
real-time PCR reaction according to the TaqMan Univer-
sal Master Mix II protocol. Each sample was analyzed in 
triplicate.
Interferon  response.  HeLa-EGFP  cells  were  transfected, 
total  RNA  was  isolated,  and  cDNA  was  synthesized  as 
described  above.  As  a  positive  control,  HeLa-EGFP  cells 
were transfected with 100 ng of Poly(I:C) complexed with 
3  µl  HiPerFect  in  100  µl  Opti-MEM  and  incubated  for  24 
hours  at  37  °C.  RNA  isolation  and  cDNA  synthesis  were 
then carried out as described above. Expression levels of 
interferon-β, CDKL2, and OAS1 were quantified with real-
time  PCR  as  described  above  using  Power  SYBR  Green 
Master  Mix  (Invitrogen)  and  specific  primer  sets:  inter-
feron-β  (IFNB)-For  5′AGACTTACAGGTTACCTCCGAA, 
IFNB-Rev  5′CAGTACATTCGCCATCAGTCA,  OAS1-For   
5′CGAGGGAGCATGAAAACACATTT, OAS1-Rev 5′GCAGA 
GTTGCTGGTAGTTTATGAC, CDKL2-For 5′GCCTCCTTGG 
GTTCGTCTATAA, CDKL2-Rev 5′CTCAGGGCCCGCTCATA 
GTA.  RPLP0  was  used  for  normalization  purposes.  Each 
sample was analyzed in triplicate (Supplementary Figures 
S5 and S6).
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Figure S10. SNALP stability at 4 °C.
Acknowledgments.  This  work  was  supported  by  funding 
from Stand Up 2 Cancer, the Marion Bessin Liver Research 
Center  at  the  Albert  Einstein  College  of  Medicine  and  the 
National Cancer Institute at the National Institutes of Health 
(1R21CA157366). M.L. and S.E.W. would like to thank Deb-
bie Palliser, Teresa P. DiLorenzo, Gayatri Mukherjee, and Joe 
Katakowski for our weekly discussions on liposomes and the 
targeted delivery of siRNA.
  1.  Daniels, TR, Delgado, T, Helguera, G and Penichet, ML (2006). The transferrin recep-
tor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 121: 
159–176.Molecular Therapy–Nucleic Acids
An RNA Alternative to Human Transferrin
Wilner et al
14
  2.  Daniels, TR, Delgado, T, Rodriguez, JA, Helguera, G and Penichet, ML (2006). The trans-
ferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of 
cancer. Clin Immunol 121: 144–158.
  3.  Jones, AR and Shusta, EV (2007). Blood-brain barrier transport of therapeutics via recep-
tor-mediation. Pharm Res 24: 1759–1771.
  4.  Head, JF, Wang, F and Elliott, RL (1997). Antineoplastic drugs that interfere with iron 
metabolism in cancer cells. Adv Enzyme Regul 37: 147–169.
  5.  Laske, DW, Muraszko, KM, Oldfield, EH, DeVroom, HL, Sung, C, Dedrick, RL et al. 
(1997). Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery 
41: 1039–49; discussion 1049.
  6.  Laske, DW, Youle, RJ and Oldfield, EH (1997). Tumor regression with regional distribu-
tion of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3: 
1362–1368.
  7.  Weaver, M and Laske, DW (2003). Transferrin receptor ligand-targeted toxin conjugate 
(Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65: 3–13.
  8.  Mendonça, LS, Firmino, F, Moreira, JN, Pedroso de Lima, MC and Simões, S (2010). 
Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for 
chronic myeloid leukemia treatment. Bioconjug Chem 21: 157–168.
  9.  Sahoo, SK, Ma, W and Labhasetwar, V (2004). Efficacy of transferrin-conjugated paclitaxel-
loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 112: 335–340.
 10.  Matsumura, Y and Maeda, H (1986). A new concept for macromolecular therapeutics in 
cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitu-
mor agent smancs. Cancer Res 46(12 Pt 1): 6387–6392.
 11.  Bartlett, DW, Su, H, Hildebrandt, IJ, Weber, WA and Davis, ME (2007). Impact of tumor-
specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by 
multimodality in vivo imaging. Proc Natl Acad Sci USA 104: 15549–15554.
 12.  Engler, JA, Lee, JH, Collawn, JF and Moore, BA (2001). Receptor mediated uptake of 
peptides that bind the human transferrin receptor. Eur J Biochem 268: 2004–2012.
 13.  Chen, CH, Dellamaggiore, KR, Ouellette, CP, Sedano, CD, Lizadjohry, M, Chernis, GA et 
al. (2008). Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci USA 
105: 15908–15913.
 14.  Magalhães, ML, Byrom, M, Yan, A, Kelly, L, Li, N, Furtado, R et al. (2012). A general RNA 
motif for cellular transfection. Mol Ther 20: 616–624.
 15.  Padilla, R and Sousa, R (1995). Mutant T7 RNA-polymerase as a DNA-polymerase. Embo 
Journal 14: 4609–4621.
 16.  Padilla, R and Sousa, R (1999). Efficient synthesis of nucleic acids heavily modified with 
non-canonical ribose 2’-groups using a mutantT7 RNA polymerase (RNAP). Nucleic Acids 
Res 27: 1561–1563.
 17.  Pieken, WA, Olsen, DB, Benseler, F, Aurup, H and Eckstein, F (1991). Kinetic charac-
terization  of  ribonuclease-resistant  2’-modified  hammerhead  ribozymes.  Science  253: 
314–317.
 18.  Schmid, SL and Carter, LL (1990). ATP is required for receptor-mediated endocytosis in 
intact cells. J Cell Biol 111(6 Pt 1): 2307–2318.
  19.  Ritchie, RF, Palomaki, GE, Neveux, LM, Navolotskaia, O, Ledue, TB and Craig, WY 
(2002). Reference distributions for serum iron and transferrin saturation: a practical, 
simple, and clinically relevant approach in a large cohort. J Clin Lab Anal 16: 237–
245.
  20.  Isselbacher, KJ, Braunwald, E, Wilson, JD, Martin, JB, Fauci, AS and Kasper, DL 
(1994). Harrison’s Principles of Internal Medicine, 13th edn. McGraw-Hill: 
New York.
 21.  Young, SP, Bomford, A and Williams, R (1984). The effect of the iron saturation of transfer-
rin on its binding and uptake by rabbit reticulocytes. Biochem J 219: 505–510.
 22.  Jeffs, LB, Palmer, LR, Ambegia, EG, Giesbrecht, C, Ewanick, S and MacLachlan, I (2005). 
A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. 
Pharm Res 22: 362–372.
 23.  Zimmermann, TS, Lee, AC, Akinc, A, Bramlage, B, Bumcrot, D, Fedoruk, MN et al. (2006). 
RNAi-mediated gene silencing in non-human primates. Nature 441: 111–114.
 24.  Heyes, J, Palmer, L, Bremner, K and MacLachlan, I (2005). Cationic lipid saturation influ-
ences intracellular delivery of encapsulated nucleic acids. J Control Release 107: 276–287.
 25.  Whitehead, KA, Langer, R and Anderson, DG (2009). Knocking down barriers: advances 
in siRNA delivery. Nat Rev Drug Discov 8: 129–138.
 26.  Zhou, J and Rossi, JJ (2011). Cell-specific aptamer-mediated targeted drug delivery. Oli-
gonucleotides 21: 1–10.
 27.  Dua, P, Kim, S and Lee, DK (2011). Nucleic acid aptamers targeting cell-surface proteins. 
Methods 54: 215–225.
 28.  Davis, ME (2009). The first targeted delivery of siRNA in humans via a self-assem-
bling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6: 
659–668.
 29.  Davis, ME, Zuckerman, JE, Choi, CH, Seligson, D, Tolcher, A, Alabi, CA et al. (2010). 
Evidence of RNAi in humans from systemically administered siRNA via targeted nanopar-
ticles. Nature 464: 1067–1070.
 30.  Calando Pharmaceuticals. Safety Study of CALAA-01 to Treat Solid Tumor Cancers. In: 
ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 20111006. 
Available from: URL of the record NLM Identifier: NCT00689065.
 31.  Yu, YJ, Zhang, Y, Kenrick, M, Hoyte, K, Luk, W, Lu, Y et al. (2011). Boosting brain uptake 
of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 3: 
84ra44.
 32.  Ni, X, Zhang, Y, Ribas, J, Chowdhury, WH, Castanares, M, Zhang, Z et al. (2011). Pros-
tate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. 
J Clin Invest 121: 2383–2390.
  33.  Zhou, J, Swiderski, P, Li, H, Zhang, J, Neff, CP, Akkina, R et al. (2009). Selec-
tion, characterization and application of new RNA HIV gp 120 aptamers for facile 
delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 37: 
3094–3109.
 34.  Zhou, J, Li, H, Li, S, Zaia, J and Rossi, JJ (2008). Novel dual inhibitory function aptamer-
siRNA delivery system for HIV-1 therapy. Mol Ther 16: 1481–1489.
 35.  Wheeler, LA, Trifonova, R, Vrbanac, V, Basar, E, McKernan, S, Xu, Z et al. (2011). Inhibi-
tion of HIV transmission in human cervicovaginal explants and humanized mice using CD4 
aptamer-siRNA chimeras. J Clin Invest 121: 2401–2412.
 36.  McNamara, JO 2nd, Andrechek, ER, Wang, Y, Viles, KD, Rempel, RE, Gilboa, E et al. 
(2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 
24: 1005–1015.
 37.  Dassie, JP, Liu, XY, Thomas, GS, Whitaker, RM, Thiel, KW, Stockdale, KR et al. (2009). 
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of 
PSMA-expressing tumors. Nat Biotechnol 27: 839–849.
 38.  Dhar, S, Gu, FX, Langer, R, Farokhzad, OC and Lippard, SJ (2008). Targeted delivery 
of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG 
nanoparticles. Proc Natl Acad Sci USA 105: 17356–17361.
 39.  Farokhzad, OC, Cheng, J, Teply, BA, Sherifi, I, Jon, S, Kantoff, PW et al. (2006). Targeted 
nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci 
USA 103: 6315–6320.
 40.  Mann, AP, Bhavane, RC, Somasunderam, A, Liz Montalvo-Ortiz, B, Ghaghada, KB, Volk, 
D et al. (2011). Thioaptamer conjugated liposomes for tumor vasculature targeting. Onco-
target 2: 298–304.
 41.  Kang, H, O’Donoghue, MB, Liu, H and Tan, W (2010). A liposome-based nanostructure for 
aptamer directed delivery. Chem Commun (Camb) 46: 249–251.
 42.  Tan, L, Neoh, KG, Kang, ET, Choe, WS and Su, X (2011). PEGylated anti-MUC1 aptamer-
doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells. Macromol 
Biosci 11: 1331–1335.
 43.  Judge, AD, Robbins, M, Tavakoli, I, Levi, J, Hu, L, Fronda, A et al. (2009). Confirming the 
RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin 
Invest 119: 661–673.
 44.  Tekmira Pharmaceuticals Corporation. Dose Escalation Study to Determine Safety, Pharma-
cokinetics, and Pharmacodynamics of Intravenous TKM-080301. In: ClinicalTrialsgov [Inter-
net] Bethesda (MD): National Library of Medicine (US) 20111006. Available from: URL of 
the record NLM Identifier: NCT01262235.
 45.  (NCI) NCI. TKM 080301 for Primary or Secondary Liver Cancer. In: ClinicalTrialsgov [Inter-
net] Bethesda (MD): National Library of Medicine (US) 20111006. Available from: URL of 
the record NLM Identifier: NCT01437007.
 46.  Akinc, A, Querbes, W, De, S, Qin, J, Frank-Kamenetsky, M, Jayaprakash, KN et al. 
(2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-
based mechanisms. Mol Ther 18: 1357–1364.
 47.  Jeffs, LB, Palmer, LR, Ambegia, EG, Giesbrecht, C, Ewanick, S and MacLachlan, I (2005). 
A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. 
Pharm Res 22: 362–372.
 48.  Hall, B, Micheletti, JM, Satya, P, Ogle, K, Pollard, J and Ellington, AD (2009). Design, 
synthesis, and amplification of DNA pools for in vitro selection. Curr Protoc Nucleic Acid 
Chem Chapter 9: Unit 9.2.
 49.  Wong,  I  and  Lohman,  TM  (1993).  A  double-filter  method  for  nitrocellulose-filter   
binding: application to protein-nucleic acid interactions. Proc Natl Acad Sci USA 90: 
5428–5432.
 50.  McGraw, TE and Subtil, A (2001). Endocytosis: biochemical analyses. Curr Protoc Cell Biol 
Chapter 15: Unit 15.3.
 51.  Reulen, SW, Brusselaars, WW, Langereis, S, Mulder, WJ, Breurken, M and Merkx, M 
(2007). Protein-liposome conjugates using cysteine-lipids and native chemical ligation. 
Bioconjug Chem 18: 590–596.
 52.  Collingwood, MA, Rose, SD, Huang, L, Hillier, C, Amarzguioui, M, Wiiger, MT et al. 
(2008). Chemical modification patterns compatible with high potency dicer-substrate small 
interfering RNAs. Oligonucleotides 18: 187–199.
Molecular  Therapy–Nucleic  Acids  is  an  open-access 
journal published by Nature Publishing Group. This work is   
licensed under the Creative Commons Attribution-Noncommercial-No   
Derivative Works 3.0 Unported License.To view a copy of this license, 
visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)